Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese
Executive Summary
Over one-third of practicing physicians cave in to patient requests for a brand-name drug over a generic, but can the trend hold? Also, deals by Baxter/Xenetic, AstraZeneca/FOB, Galectin/SBH, Biogen/UCB and Actavis/Zhejiang Chiral Medicine Chemicals.
You may also be interested in...
An Antibiotic Anniversary Celebration: Deal-Making and Investment Are Active In Formerly Moribund Field
A year ago, the Pew Trust hosted a meeting on antibiotic development that emphasized the many barriers still discouraging investment in the field despite new legislation (the GAIN Act). Three coincidental announcements in early 2014 show that the development freeze in anti-infectives is beginning to thaw.
Biogen Sets Aside Cash For Business Development, Expects New Launches In 2014
The spec pharma had a strong year and will continue to rely on new product launches going forward, but hopes to bolster its pipeline with early-stage add-ons.
People Power: How The Crowd May Shape The Funding And Development Of Drugs
Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.